<DOC>
	<DOCNO>NCT02834546</DOCNO>
	<brief_summary>The aim pilot study correlate sorafenib plasma concentration observe toxicity disease control rate 100 patient undergoing palliative treatment hepatocellular carcinoma ( HCC ) . If correlation observe , consider plan large interventional study adjust sorafenib daily dose plasma concentration .</brief_summary>
	<brief_title>Correlation Between Sorafenib Plasma Concentrations , Toxicity Disease Control Rate Patients Treated Sorafenib Hepatocellular Carcinoma</brief_title>
	<detailed_description>Sorafenib standard care palliative treatment HCC . The recommend dose sorafenib patient HCC 400 mg twice daily . Sorafenib dose-limiting toxicity include diarrhea , arterial hypertension hand-foot syndrome . Owing large inter-patient variability ( near 50 % ) sorafenib Area Under Curve ( AUC ) 12h , over-exposure sorafenib could explain acute toxicity . On hand , suboptimal exposure could result insufficient anti-tumor activity suggest recent study . This inter-patient variability sorafenib pharmacokinetic especially relevant HCC . Indeed , HCC develop cirrhotic liver often impaired liver function , decrease albuminemia sometimes ascitis . All parameter likely impact sorafenib pharmacokinetic . The aim pilot study correlate sorafenib plasma concentration observe toxicity disease control rate 100 patient . The dose sorafenib recommend dose : 400 mg twice daily . Sorafenib daily dos adjust clinician adverse event . Values sorafenib AUC transmit clinician . Patients follow 12 month 5 visit : Week 4 , Week 8 , Week 16 , Month 6 Month 12 . Adverse event relate sorafenib record grade accord NCI-CTC Adverse Event study period . Sorafenib plasma concentration assess 4 , 8 16 week . An additional dosage could perform W1 W4 , dose modification , dose modification necessary due adverse event W4 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Subjects &gt; 18 year age Possibility regular monitoring Ability understand willingness sign write informed consent . Hepatocellular carcinoma histologically diagnose case inability perform histology noninvasive radiological criterion endorse EASL/AASLD ( ) presence know cirrhosis ( b ) identification focal hepatic lesion measure least 1cm diameter contrast uptake arterial phase rapid wash venous /late phase two image technique Patient eligible curative treatment ( transplantation , resection , destruction percutaneous chemoembolization ) HCC still evolve failure specific treatment ECOG â‰¤ 2 ChildPugh A B Score BCLC B C Any condition unstable could jeopardize safety subject compliance study Cirrhosis CHILD C Score BCLC D ECOG &gt; 2 Digestive bleeding within 30 day inclusion Subject liver transplant wait liver transplant Subject previously treat sorafenib Childbearing breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Plasmatic concentration</keyword>
</DOC>